ANALYSIS: As Vital Healthcare revives a restructuring scheme, directors of its external manager seem particularly antsy about their independence.
ANALYSIS: While property developer Winton is sitting pretty after a perfectly timed IPO, its investors won’t be so happy.
ANALYSIS: In New Zealand’s unregulated market, it’s all they’ve got to go on.
ANALYSIS: A farm investment company has given its small shareholders an uncomfortable ride.
ANALYSIS: With green bonds not necessarily green or cheaper for issuers, higher standards will be required to deliver on promises.
ANALYSIS: As Genesis mulls burning wood pellets at Huntly power station, their contribution to renewable energy targets is under fire in Europe.
ANALYSIS: The Ombudsman rules a secret DIA report can stay secret.
ANALYSIS: A deal to sell Evolve Education’s NZ business raises questions of value for shareholders.
Expectations of the gains from Covid for Fisher & Paykel were bullish, until they weren’t.
ANALYSIS: Lessons should be learned as Marlborough Lines seeks a partial exit from its wine subsidiary to fund investment in electricity.
